Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Eun Hee JungHee Ryeong JangSe Hyun KimKoung Jin SuhYu Jung KimJu-Hyun LeeJin-Haeng ChungMiso KimBhumsuk KeamTae Min KimDong Wan KimDae Seog HeoJong Seok LeePublished in: Thoracic cancer (2021)
Patients with NSCLC who co-express NY-ESO-1 or LAG-3 with PD-L1 exhibit greater DCBs and improved long-term survival following anti-PD-1 therapy. Moreover, NY-ESO-1 and LAG-3 could be novel predictive biomarkers of survival and should be considered in the future use of ICIs.